UNCY
Unicycive Therapeutics, Inc.
$5.09
-0.12 (-2.30%)
At close · Jul 13
Market Cap
$135.90M
Shares
26,700,027
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.09
Open$5.19
Day$4.93–5.19
52W$3.71–8.74
Avg vol 30d2.3M
Short int4.7M · 17.5% float · 1.2d
Short vol43%
DataJul 2021–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−29%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
−18%
trailing
YTD return
−12%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+46% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.50% of float · ▲ +44.3% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
51 holders — near 1-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−29%
Y/Y
EPS growth
+70%
Y/Y
Free cash flow
$-31.3M
Balance sheet
$29.2M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+46% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.50% of float · ▲ +44.3% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
51 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $5 · 27%
52-wk high $9
vs 200-day avg -19%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UNCY
this stock
Unicycive Therapeutics, Inc.
|
$135.90M | -11.8% | -29.0% | — | 17.5% |
|
ONC
BeOne Medicines Ltd.
|
$439.30B | +0.0% | +22179.2% | 894.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$120.89B | +5.1% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.79B | -14.9% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$53.77B | +2.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UNCY | -5.0% | -33.8% | -17.8% | +8.5% | -11.8% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | -4.8% | -35.4% | -26.1% | +8.2% | -21.7% |